Evolutionary druggability for low-dimensional fitness landscapes toward new metrics for antimicrobial applications
The term 'druggability' describes the molecular properties of drugs or targets in pharmacological interventions and is commonly used in work involving drug development for clinical applications. There are no current analogues for this notion that quantify the drug-target interaction with r...
Saved in:
Published in | eLife Vol. 12 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
eLife Sciences Publications Ltd
04.06.2024
eLife Sciences Publications, Ltd |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The term 'druggability' describes the molecular properties of drugs or targets in pharmacological interventions and is commonly used in work involving drug development for clinical applications. There are no current analogues for this notion that quantify the drug-target interaction with respect to a given target variant's sensitivity across a breadth of drugs in a panel, or a given drug's range of effectiveness across alleles of a target protein. Using data from low-dimensional empirical fitness landscapes composed of 16 β-lactamase alleles and 7 β-lactam drugs, we introduce two metrics that capture (i) the average susceptibility of an allelic variant of a drug target to any available drug in a given panel ('
), and (ii) the average applicability of a drug (or mixture) across allelic variants of a drug target ('
'). Finally, we (iii) disentangle the quality and magnitude of interactions between loci in the drug target and the seven drug environments in terms of their mutation by mutation by environment (G x G x E) interactions, offering mechanistic insight into the variant variability and drug applicability metrics. Summarizing, we propose that our framework can be applied to other datasets and pathogen-drug systems to understand which pathogen variants in a clinical setting are the most concerning (low variant vulnerability), and which drugs in a panel are most likely to be effective in an infection defined by standing genetic variation in the pathogen drug target (high drug applicability). |
---|---|
AbstractList | The term ‘druggability’ describes the molecular properties of drugs or targets in pharmacological interventions and is commonly used in work involving drug development for clinical applications. There are no current analogues for this notion that quantify the drug-target interaction with respect to a given target variant’s sensitivity across a breadth of drugs in a panel, or a given drug’s range of effectiveness across alleles of a target protein. Using data from low-dimensional empirical fitness landscapes composed of 16 β-lactamase alleles and 7 β-lactam drugs, we introduce two metrics that capture (i) the average susceptibility of an allelic variant of a drug target to any available drug in a given panel (‘variant vulnerability’), and (ii) the average applicability of a drug (or mixture) across allelic variants of a drug target (‘drug applicability’). Finally, we (iii) disentangle the quality and magnitude of interactions between loci in the drug target and the seven drug environments in terms of their mutation by mutation by environment (G x G x E) interactions, offering mechanistic insight into the variant variability and drug applicability metrics. Summarizing, we propose that our framework can be applied to other datasets and pathogen-drug systems to understand which pathogen variants in a clinical setting are the most concerning (low variant vulnerability), and which drugs in a panel are most likely to be effective in an infection defined by standing genetic variation in the pathogen drug target (high drug applicability). The term ‘druggability’ describes the molecular properties of drugs or targets in pharmacological interventions and is commonly used in work involving drug development for clinical applications. There are no current analogues for this notion that quantify the drug-target interaction with respect to a given target variant’s sensitivity across a breadth of drugs in a panel, or a given drug’s range of effectiveness across alleles of a target protein. Using data from low-dimensional empirical fitness landscapes composed of 16 β-lactamase alleles and 7 β-lactam drugs, we introduce two metrics that capture (i) the average susceptibility of an allelic variant of a drug target to any available drug in a given panel (‘ variant vulnerability’ ), and (ii) the average applicability of a drug (or mixture) across allelic variants of a drug target (‘ drug applicability ’). Finally, we (iii) disentangle the quality and magnitude of interactions between loci in the drug target and the seven drug environments in terms of their mutation by mutation by environment (G x G x E) interactions, offering mechanistic insight into the variant variability and drug applicability metrics. Summarizing, we propose that our framework can be applied to other datasets and pathogen-drug systems to understand which pathogen variants in a clinical setting are the most concerning (low variant vulnerability), and which drugs in a panel are most likely to be effective in an infection defined by standing genetic variation in the pathogen drug target (high drug applicability). The term 'druggability' describes the molecular properties of drugs or targets in pharmacological interventions and is commonly used in work involving drug development for clinical applications. There are no current analogues for this notion that quantify the drug-target interaction with respect to a given target variant's sensitivity across a breadth of drugs in a panel, or a given drug's range of effectiveness across alleles of a target protein. Using data from low-dimensional empirical fitness landscapes composed of 16 β-lactamase alleles and 7 β-lactam drugs, we introduce two metrics that capture (i) the average susceptibility of an allelic variant of a drug target to any available drug in a given panel (' ), and (ii) the average applicability of a drug (or mixture) across allelic variants of a drug target (' '). Finally, we (iii) disentangle the quality and magnitude of interactions between loci in the drug target and the seven drug environments in terms of their mutation by mutation by environment (G x G x E) interactions, offering mechanistic insight into the variant variability and drug applicability metrics. Summarizing, we propose that our framework can be applied to other datasets and pathogen-drug systems to understand which pathogen variants in a clinical setting are the most concerning (low variant vulnerability), and which drugs in a panel are most likely to be effective in an infection defined by standing genetic variation in the pathogen drug target (high drug applicability). |
Author | Dorji, Tandin Ogbunugafor, C Brandon Guerrero, Rafael F Harris, Ra'Mal M Shoulders, Matthew D |
Author_xml | – sequence: 1 givenname: Rafael F orcidid: 0000-0002-8451-3609 surname: Guerrero fullname: Guerrero, Rafael F organization: Department of Biological Sciences, North Carolina State University, Raleigh, United States – sequence: 2 givenname: Tandin surname: Dorji fullname: Dorji, Tandin organization: Department of Mathematics and Statistics, University of Vermont, Burlington, United States – sequence: 3 givenname: Ra'Mal M orcidid: 0000-0002-9537-371X surname: Harris fullname: Harris, Ra'Mal M organization: Department of Chemistry, Massachusetts Institute of Technology, Cambridge, United States – sequence: 4 givenname: Matthew D orcidid: 0000-0002-6511-3431 surname: Shoulders fullname: Shoulders, Matthew D organization: Department of Chemistry, Massachusetts Institute of Technology, Cambridge, United States – sequence: 5 givenname: C Brandon orcidid: 0000-0002-1581-8345 surname: Ogbunugafor fullname: Ogbunugafor, C Brandon organization: Public Health Modeling Unit, Yale School of Public Health, New Haven, United States |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38833384$$D View this record in MEDLINE/PubMed |
BookMark | eNpdkU1v1DAQhi0EomXpiTuKxIVLij9j54RQVWillbiAxC1y7PHilRMH2-mq_77etlSUuYw0fufxOzNv0Ms5zoDQO4LPpRD8E2y9g3OluMIv0CnFArdY8V8n6CznPa4huVKkf41OmFKMMcVPUbq8iWEtPs463TY2rbudHn3w5bZxMTUhHlrrJ5jzUREa58sMOTdBzzYbvUBuSjzoZJsZDs0EJXmT7zv1XPzkTYqjr316WYI3-vhPfoteOR0ynD3mDfr59fLHxVW7_f7t-uLLtrWMqtIyyZh2XI5Osw4sc2M3YsuV6TBVfbXvRg2SW0F74QxhloKwxAIR2nChJNug6weujXo_LMlPdcQhaj_cF2LaDToVbwIMTBLuuABsFebKjlpKZWlnOj06I5irrM8PrGUdJ7AG5pJ0eAZ9_jL738Mu3gyEEN73tK-Ej4-EFP-skMsw-Wwg1E1CXPPAcMd7SmkdbIM-_CfdxzXV9R9VkinZka6rqvf_Wnry8ve27A5Jf6pL |
ContentType | Journal Article |
Copyright | 2023, Guerrero et al. 2023, Guerrero et al. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2023, Guerrero et al 2023 Guerrero et al |
Copyright_xml | – notice: 2023, Guerrero et al. – notice: 2023, Guerrero et al. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2023, Guerrero et al 2023 Guerrero et al |
DBID | CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PIMPY PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
DOI | 10.7554/eLife.88480 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) Medical Database ProQuest Science Journals Biological Science Database Publicly Available Content (ProQuest) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 2050-084X |
ExternalDocumentID | oai_doaj_org_article_3714f45e0d8048dba778d26c6abfc53f 38833384 |
Genre | Journal Article |
GrantInformation_xml | – fundername: NIH HHS grantid: R01AI168166 – fundername: NIH HHS grantid: R35GM147107 – fundername: National Science Foundation grantid: 2142720 – fundername: NIH HHS grantid: R35GM136--354 – fundername: ; grantid: R35GM136--354 – fundername: ; grantid: R35GM147107 – fundername: ; grantid: 2142720 – fundername: ; grantid: R01AI168166 |
GroupedDBID | 3V. 53G 5VS 7X7 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAKDD ABUWG ACGFO ACGOD ACPRK ADBBV ADRAZ AENEX AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI CCPQU CGR CUY CVF DIK DWQXO ECM EIF EMOBN FRP FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IEA IHR INH INR ISR ITC KQ8 LK8 M1P M2P M7P M~E NPM NQS OK1 PGMZT PIMPY PQQKQ PROAC PSQYO RHF RHI RNS RPM UKHRP 7XB 8FK K9. M48 PQEST PQUKI PRINS Q9U 7X8 5PM AFPKN |
ID | FETCH-LOGICAL-d328t-3733af47bfa36ed3fb6b0d48c60289333fbae74d5295fc13d2e5d1de15ac45873 |
IEDL.DBID | RPM |
IngestDate | Tue Oct 22 15:11:27 EDT 2024 Tue Sep 17 21:28:21 EDT 2024 Sat Oct 26 05:01:01 EDT 2024 Thu Oct 10 22:01:36 EDT 2024 Sat Nov 02 12:30:14 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | druggability evolutionary biology drug resistance E. coli evolutionary genetics |
Language | English |
License | 2023, Guerrero et al. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-d328t-3733af47bfa36ed3fb6b0d48c60289333fbae74d5295fc13d2e5d1de15ac45873 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-6511-3431 0000-0002-1581-8345 0000-0002-9537-371X 0000-0002-8451-3609 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11149929/ |
PMID | 38833384 |
PQID | 3073876166 |
PQPubID | 2045579 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_3714f45e0d8048dba778d26c6abfc53f pubmedcentral_primary_oai_pubmedcentral_nih_gov_11149929 proquest_miscellaneous_3064922233 proquest_journals_3073876166 pubmed_primary_38833384 |
PublicationCentury | 2000 |
PublicationDate | 2024-06-04 |
PublicationDateYYYYMMDD | 2024-06-04 |
PublicationDate_xml | – month: 06 year: 2024 text: 2024-06-04 day: 04 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Cambridge |
PublicationTitle | eLife |
PublicationTitleAlternate | Elife |
PublicationYear | 2024 |
Publisher | eLife Sciences Publications Ltd eLife Sciences Publications, Ltd |
Publisher_xml | – name: eLife Sciences Publications Ltd – name: eLife Sciences Publications, Ltd |
References | 37066376 - bioRxiv. 2023 Sep 06:2023.04.08.536116. doi: 10.1101/2023.04.08.536116 |
References_xml | |
SSID | ssj0000748819 |
Score | 2.4267128 |
Snippet | The term 'druggability' describes the molecular properties of drugs or targets in pharmacological interventions and is commonly used in work involving drug... The term ‘druggability’ describes the molecular properties of drugs or targets in pharmacological interventions and is commonly used in work involving drug... |
SourceID | doaj pubmedcentral proquest pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
SubjectTerms | Alleles Anti-Bacterial Agents - pharmacology Antimicrobial agents beta-Lactamases - genetics beta-Lactamases - metabolism beta-Lactams - pharmacology Drug development Drug interaction Drug resistance druggability Evolution, Molecular Evolutionary Biology evolutionary genetics Genetic diversity Genetic Fitness Genotype & phenotype Mutation Pathogens Therapeutic targets Topography Viral infections β Lactamase β-Lactam antibiotics |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dS8MwEA-yJ19E8as6JYKvZWuTpumjijJEfFLYW8nnLLhOtk7Zf-9dWmUTwRdfkwaud5fLL9zld4Rcmoy7QigbO9xuXOciVsIVsdcAZjOPpFOhQPZRjJ75_Tgbr7X6wpqwlh64VdwAGeU8z9zQSnA2q1WeS5sKI5T2JmM-RN9hunaZCjE4B8dMivZBXg5H5sA9VN6BW3AkgAz0_L9hyp-lkWtnzd0u2elAIr1qhdsjW67eJ_Pb985N1HxF7Xw5mbQc2ysKwJO-zj5ii1T9Lc0G9VWDUYyGt7xY5bSgTSiRpQCk6RQbaZlFWAm6raZVIGSCdesZ7QPyfHf7dDOKu44JsWWpbCBaMKY8z7VXTDjLvBZ6aLk0AhOKjMGAcjm3mN3zJmE2dZlNrEsyZXgmc3ZIevWsdseEMqm0MUwJ1F7ikKa-EGnqjJVeMzGMyDUqsXxrSTFKpKkOA2C8sjNe-ZfxItL_MkHZ7Z1FiVEHYnQiREQuvqfB6zGVoWo3W-I3ghcIbVhEjlqLfUvCsH8ykzwicsOWG6JuztTVS2DWhsAPN8C0OPmPnzsl2ykgoFBXxvuk18yX7gwQTKPPg7N-AqqB9Uc priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwELYoXLhUVLxSKDIS14hN7NjOqYIKhBDiBNLeIj-XSJDQbLYV_74zTtiyCHG1Y8nyvL54xt8QcmIL7kuhXerR3LiRItXCl2kwAGaLgKRTsUD2Vlzd8-tpMR0v3OZjWeWrT4yO2rUW78hPURfBcjMhfj7_TrFrFGZXxxYaX8hGlkMoB32WU7m8Y4HwqCDiDc_yJATOU39TBw_KwZEGMpL0f4Qs3xdIvok4l1vk6wgV6dkg229kzTfbpLv4MyqL7l6o6xaz2cC0_UIBftLH9m_qkLB_INugoe7Rl9H4ohdrnea0j4WyFOA0fcJ2WnYeV8IJ1091pGWCdW_z2jvk_vLi7tdVOvZNSB3LVQ8-gzEduDRBM-EdC0aYiePKCkwrMgYD2kvuMMcXbMZc7guXOZ8V2vJCSbZL1pu28fuEMqWNtUwLPL3MI1l9KfLcW6eCYWKSkHM8xOp5oMaokKw6DrTdrBp1v0JSwMALP3EK_IUzWkrlcmGFNsEWLCTk8FUE1WhB8-q_vBNyvJwG3ceEhm58u8BvBC8R4LCE7A0SW-6EYRdlpnhC1IosV7a6OtPUD5FfG9w__Afm5ffP93VANnNAOLFujB-S9b5b-B-AUHpzFNXwH3NO7E8 priority: 102 providerName: ProQuest |
Title | Evolutionary druggability for low-dimensional fitness landscapes toward new metrics for antimicrobial applications |
URI | https://www.ncbi.nlm.nih.gov/pubmed/38833384 https://www.proquest.com/docview/3073876166 https://www.proquest.com/docview/3064922233 https://pubmed.ncbi.nlm.nih.gov/PMC11149929 https://doaj.org/article/3714f45e0d8048dba778d26c6abfc53f |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Na9wwEBVJeumlpKQfbtJFhV6dXVuyJB-bsCGUNITSwN6MPreGrDd4vS35952R7bBbeurVtkDWPI2ePU9PhHy2Bfel0C71ON24kSLVwpdpMEBmi4CmU1Egeyuu7_nXRbE4IGLcCxNF-9bU583D6rypf0Zt5ePKTked2PTu2yXMTyDqeTk9JIew_u58o8f8KwGUWdlvxpOwXE79TR08QIIrPPiN4fm6LNqZogLtX9Tyb4XkzpJzdUxeDVyRfun79Joc-OaEtPNfA1p0-0Rdu10ue6vtJwr8kz6sf6cOHft7tw0a6g6TGY1belHstKFdVMpS4NN0hedp2U1sCUNcr-roywTtdgvbb8j91fzH5XU6HJyQOparDpIGYzpwaYJmwjsWjDAzx5UVWFeElw9Ge8kdFvmCzZjLfeEy57NCW14oyd6So2bd-PeEMqWNtUwLHMjMo1t9KfLcW6eCYWKWkAscxOqx98ao0K06Xli3y2qIWYWugIEXfuYUJAxntJTK5cIKbYItWEjI2RiCaphCmwqTD6TqTIiEfHq-DeDHioZu_HqLzwheIsNhCXnXR-y5J2OYE6L2YrnX1f07gLdosD3i68P_Nz0lL3OgP1FUxs_IUddu_UegL52ZAGYXckJeXMxv775P4k-ASUTwH35J-Ss |
link.rule.ids | 230,314,727,780,784,864,885,2102,12056,21388,27924,27925,31719,31720,33744,33745,43310,43805,53791,53793,73745,74302 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZge4ALAvFKKWAkrlE3seM4p4qirRZYVgi1Um-Rn0skmrTZLKj_vjOOu3QR4mrHkuV5ffGMvyHkvSm4q4SyqUNz47oUqRKuSr0GMFt4JJ0KBbJLMT_jn8-L83jhto5llbc-MThq2xm8Iz9EXQTLzYQ4urxKsWsUZldjC437ZA-Z04sJ2TueLb99396yQICUEPPGh3klhM5Dt2i8A_XgSAQZaPr_hS3_LpG8E3NOHpNHESzSD6N0n5B7rn1K-tmvqC6qv6a236xWI9f2NQUASn92v1OLlP0j3Qb1zYDejIY3vVjttKZDKJWlAKjpBTbUMuuwEs64uWgCMROsu5vZfkbOTmanH-dp7JyQWpbLAbwGY8rzUnvFhLPMa6GnlksjMLHIGAwoV3KLWT5vMmZzV9jMuqxQhheyZM_JpO1a95JQJpU2himBp5c5pKuvRJ47Y6XXTEwTcoyHWF-O5Bg10lWHga5f1VH7a6QF9LxwUyvBY1itylLaXBihtDcF8wk5uBVBHW1oXf-ReELebadB-zGloVrXbfAbwSuEOCwhL0aJbXfCsI8ykzwhckeWO1vdnWmbH4FhGwIA_Anm1f7_9_WWPJiffl3Ui0_LL6_IwxzwTqgi4wdkMvQb9xrwyqDfRKW8AbGs8KU |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZgKyEuCMQrpYCRuEa7iR3HOVUUdlWgWlWISr1Ffi6RaNJms6D--8447tJFiKsdS5bn9cUz_oaQ96bgrhLKpg7NjetSpEq4KvUawGzhkXQqFMguxfEZ_3JenMf6p3Usq7z1icFR287gHfkUdREsNxNi6mNZxOmnxeHlVYodpDDTGttp3Cd7EBVn-YTsHc2Xp9-2Ny4QLCXEv_GRXglhdOpOGu9AVTiSQgbK_n_hzL_LJe_En8Vj8igCR_phlPQTcs-1T0k__xVVR_XX1Pab1Wrk3b6mAEbpz-53apG-f6TeoL4Z0LPR8L4XK5_WdAhlsxTANb3A5lpmHVbCeTcXTSBpgnV3s9zPyNli_v3jcRq7KKSW5XIAD8KY8rzUXjHhLPNa6Jnl0ghMMjIGA8qV3GLGz5uM2dwVNrMuK5ThhSzZczJpu9a9JJRJpY1hSuDpZQ6p6yuR585Y6TUTs4Qc4SHWlyNRRo3U1WGg61d1tIQaKQI9L9zMSvAeVquylDYXRijtTcF8Qg5uRVBHe1rXf6SfkHfbabAETG-o1nUb_EbwCuEOS8iLUWLbnTDsqcwkT4jckeXOVndn2uZHYNuGYAB_hXm1__99vSUPQB_rk8_Lr6_IwxygTygo4wdkMvQb9xqgy6DfRJ28AXPG9NI |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evolutionary+druggability+for+low-dimensional+fitness+landscapes+toward+new+metrics+for+antimicrobial+applications&rft.jtitle=eLife&rft.au=Guerrero%2C+Rafael+F&rft.au=Dorji%2C+Tandin&rft.au=Harris%2C+Ra%27Mal+M&rft.au=Shoulders%2C+Matthew+D&rft.date=2024-06-04&rft.eissn=2050-084X&rft.volume=12&rft_id=info:doi/10.7554%2FeLife.88480&rft.externalDBID=NO_FULL_TEXT |